Prolonged-release tablet. Mirabegron is indictaed for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Fact Table Formula C21H24N4O2S License US FDA, EU EMA Bioavailability 29–35% Legal status Rx-Only Chemical Name Mirabegron Elimination half-life 50 hours Dosage (Strength) 25mg, 50mg Pregnancy Not recommended Brands Myrbetriq Protein binding 71% PubChem CID 9865528 MedlinePlus a612038 ChEBI 65349 ATC code G04BD12 DrugBank DB08893 KEGG D09535 Routes of administration By mouth (tablets)

Myrbetriq (Mirabegron)

The recommended dose is 50 mg once daily with or without food.The tablet is to be taken once daily, with liquids, swallowed whole and is not to be chewed, divided, or crushed. The safety and efficacy of mirabegron in children below 18 years of age have not yet been established.
Mirabegron has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) and, therefore, it is not recommended for use in patient population with renal impairment. Data are limited in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2),a dose reduction to 25 mg is recommended in this population. Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in this patient population.

Myrbetriq (Mirabegron)

Directions

Ingredients

Cautions

Side Effects